Money will be used to expand the firm's platform of polymers across various therapeutic fields, including nerve repair, cardiovascular and gastroenterology.
Data demonstrates improvements in objective pelvic floor muscle measures, patient-reported urinary incontinence severity and condition-specific quality of life.